Kymera Therapeutics to Present Pre-clinical Data at the EULAR 2022 Congress Showing STAT3 Degradation Blocked Th17 Development and Prevented Rheumatoid Arthritis
01 June 2022 - 9:00PM
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage
biopharmaceutical company advancing targeted protein degradation to
deliver novel small molecule protein degrader medicines, will
present new preclinical data demonstrating that STAT3 degradation
blocked Th17 development and cytokine release and prevented
collagen-induced arthritis (CIA), a pre-clinical model of
rheumatoid arthritis, today at the EULAR 2022 Congress in
Copenhagen, Denmark.
“These data further establish proof-of-concept for Kymera’s
potent and selective STAT3 degraders in inflammatory and autoimmune
disorders,” said Anthony Slavin, Vice President,
Immunology. “Our findings demonstrate that even limited
degradation of STAT3 results in significant suppression of
proinflammatory cytokines across several immune cell types,
including monocytes and T cells. The ability to block Th17
development and cytokine release with STAT3 degradation, and the
demonstration of how that translates in vivo in a mouse model of
rheumatoid arthritis, underscores the potential for STAT3 targeting
in the treatment of Th17-driven autoimmune diseases.”
Research highlights included:
- Kymera’s investigational STAT3 degrader selectively and
potently degraded STAT3 in human peripheral blood mononuclear cells
(PBMCs) and whole blood
- STAT3 degradation abrogated STAT3 phosphorylation and
MCP-1/CCL2 release by human monocytes more potently than JAK
inhibition
- STAT3 degradation inhibited CD4+ Th17 development and related
cytokine production in vitro and prevented collagen-induced
arthritis in mice
In addition to being linked to numerous cancers, increased STAT3
activation is associated with disease severity and chronic
inflammation in conditions such as systemic sclerosis, rheumatoid
arthritis, ankylosing spondylitis, multiple sclerosis, inflammatory
bowel disease and psoriasis. Kymera has previously shown its STAT3
degraders suppressed tumor growth in multiple preclinical models of
lymphoma and solid tumors, and recently reported activity against
Th17 inflammation in experimental autoimmune encephalomyelitis
(EAE), a clinically relevant mouse model of multiple sclerosis.
“Kymera’s first-in-class heterobifunctional degraders have
emerged as a novel therapeutic modality with great potential to
drug historically ‘undruggable’ protein targets like STAT3,” said
Nello Mainolfi, PhD, Co-Founder, President and CEO, Kymera
Therapeutics. “Our STAT3 degrader KT-333 in development for liquid
and solid tumors is currently in Phase 1 and we continue to explore
the preclinical activity of our STAT3 degraders in autoimmune
indications given the substantial development opportunities for
STAT3 targeting in inflammation and fibrosis.”
Presentation details:
- Title: STAT3 degraders inhibit Th17 development and cytokine
production resulting in profound inhibition of collagen-induced
autoimmune murine arthritis
- Abstract Number: #OP0080
- Session Day/Time: Wednesday, June 1; 5:35-5:45 p.m. CEST
- Location: Bella Center Copenhagen, Copenhagen, Denmark
- Presenter: Anthony Slavin, Vice President, Immunology, Kymera
Therapeutics
About Kymera TherapeuticsKymera Therapeutics
(Nasdaq: KYMR) is a biopharmaceutical company pioneering the field
of targeted protein degradation, a transformative approach to
address disease targets and pathways inaccessible with conventional
therapeutics. Kymera’s Pegasus platform is a powerful drug
discovery engine, advancing novel small molecule therapies that
harness the body’s innate protein recycling machinery to degrade
dysregulated, disease-causing proteins. With a focus on undrugged
nodes in validated pathways, Kymera is advancing a pipeline of
novel therapeutics designed to address the most intractable
pathways and provide new treatments for patients. Kymera’s initial
programs target IRAK4, IRAKIMiD, and STAT3 within the IL-1R/TLR or
JAK/STAT pathways, providing the opportunity to treat patients with
a broad range of immune-inflammatory diseases, hematologic
malignancies, and solid tumors. For more information, visit
www.kymeratx.com.
Founded in 2016, Kymera is headquartered in Watertown, Mass.
Kymera has been named a “Fierce 15” biotechnology company by Fierce
Biotech and has been recognized by the Boston Business Journal as
one of Boston’s “Best Places to Work.” For more information about
our people, science, and pipeline, please visit www.kymeratx.com or
follow us on Twitter or LinkedIn.
Cautionary Note Regarding Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, as amended, including, without limitation,
implied and express statements regarding its: strategy, business
plans and objectives for the STAT3 degrader program; and plans and
timelines for the clinical development of Kymera Therapeutics'
product candidates, including the therapeutic potential and
clinical benefits thereof. The words "may," “might,” "will,"
"could," "would," "should," "expect," "plan," "anticipate,"
"intend," "believe," “expect,” "estimate," “seek,” "predict,"
“future,” "project," "potential," "continue," "target" and similar
words or expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. Any forward-looking statements in this
press release are based on management's current expectations and
beliefs and are subject to a number of risks, uncertainties and
important factors that may cause actual events or results to differ
materially from those expressed or implied by any forward-looking
statements contained in this press release, including, without
limitation, risks associated with: the impact of COVID-19 on
countries or regions in which we have operations or do business, as
well as on the timing and anticipated results of our current
preclinical studies and future clinical trials, strategy and future
operations; the delay of any current preclinical studies or future
clinical trials or the development of Kymera
Therapeutics' drug candidates; the risk that the results
of current preclinical studies may not be predictive of future
results in connection with future clinical trials; Kymera
Therapeutics' ability to successfully demonstrate the safety and
efficacy of its drug candidates; the timing and outcome of the
Company’s planned interactions with regulatory authorities; and
obtaining, maintaining and protecting its intellectual
property. These and other risks and uncertainties are
described in greater detail in the section entitled "Risk Factors"
in the Quarterly Report on Form 10-Q for the period ended March 31,
2022, filed on May 3, 2022, as well as discussions of potential
risks, uncertainties, and other important factors in Kymera
Therapeutics' subsequent filings with the Securities and Exchange
Commission. In addition, any forward-looking statements represent
Kymera Therapeutics' views only as of today and should not be
relied upon as representing its views as of any subsequent date.
Kymera Therapeutics explicitly disclaims any obligation to update
any forward-looking statements. No representations or warranties
(expressed or implied) are made about the accuracy of any such
forward-looking statements.
Investor Contact:Bruce Jacobs Chief Financial
Officer investors@kymeratx.com857-285-5300
Chris BrinzeyManaging Director,
Westwickechris.brinzey@westwicke.com339-970-2843
Media Contact:Todd CooperSenior Vice President,
Corporate Affairsmedia@kymeratx.com857-285-5300
Kymera Therapeutics (NASDAQ:KYMR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Kymera Therapeutics (NASDAQ:KYMR)
Historical Stock Chart
From Jul 2023 to Jul 2024